Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Company
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (97.3%). Net sales break down by treatment area between oncology (41.9%), cardiovascular, renal and metabolic diseases (27.4%), respiratory and autoimmune diseases (20.7%), and other (10%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (2.7%).

Net sales are distributed geographically as follows: the United Kingdom (6.5%), Continental Europe (18.2%), Americas (38.7%) and Africa/Asia/Australia (36.6%).

Number of employees : 76 100 people.
Sales per Business
20192020Delta
GBP (in Million)%GBP (in Million)%
Oncology6,79435.5%8,46139.3% +24.54%
Cardiovascular, Renal & Metabolism5,41328.3%5,53425.7% +2.22%
Respiratory4,22622.1%4,17719.4% -1.14%
Other Diseases2,03910.7%2,0179.4% -1.05%
Externalisation Revenue641.983.4%566.932.6% -11.69%
Sales per region
2020
GBP (in Million)%
United States6,98332.5%
China4,16819.4%
Japan2,0029.3%
United Kingdom1,3586.3%
Other Asia, Africa and Australasia1,1965.6%
Other Continental Europe1,0855%
Sweden800.093.7%
Germany730.693.4%
Other Americas593.442.8%
France509.222.4%
Managers
NameAgeSinceTitle
Pascal Soriot602012Chief Executive Officer & Executive Director
Marc Dunoyer682013Chief Financial Officer & Executive Director
Menelas Pangalos-2019EVP-Biopharmaceuticals Research & Development
Pam Cheng492015Executive VP-Operations & Information Technology
Henry Cremisi--Medical Director
Hasan Jafri, Dr.--Senior Medical Director
Katarina Ageborg-2017Chief Compliance Officer & EVP-Sustainability
Marcus Wallenberg641999Independent Non-Executive Director
Leif Johansson692012Non-Executive Chairman
Philip Arthur John Broadley592021Senior Independent Non-Executive Director
Members of the board
NameAgeSinceTitle
Leif Johansson692012Non-Executive Chairman
Marcus Wallenberg641999Independent Non-Executive Director
Marc Dunoyer682013Chief Financial Officer & Executive Director
Pascal Soriot602012Chief Executive Officer & Executive Director
Philip Arthur John Broadley592021Senior Independent Non-Executive Director
Nazneen Rahman, Dr.-2017Independent Non-Executive Director
Sherilyn McCoy612017Independent Non-Executive Director
Deborah DiSanzo602017Independent Non-Executive Director
Tony Mok, Dr.592019Independent Non-Executive Director
Michel Demaré642019Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,312,762,006 1,256,906,517 95.7% 0 0.0% 95.7%
Shareholders
NameEquities%
Wellington Management Co. LLP 68,525,329 5.22%
Capital Research & Management Co. (World Investors) 56,102,804 4.27%
BlackRock Investment Management (UK) Ltd. 54,582,684 4.16%
Investor AB (Investment Company) 51,587,810 3.93%
The Vanguard Group, Inc. 35,137,408 2.68%
Norges Bank Investment Management 30,410,000 2.32%
BlackRock Fund Advisors 24,843,394 1.89%
BlackRock Advisors (UK) Ltd. 17,081,041 1.30%
SSgA Funds Management, Inc. 13,640,628 1.04%
Clearstream Banking SA 12,010,000 0.91%
Holdings
NameEquities%Valuation
AstraZeneca Pharma India Limited (506820) 18,750,00075.0%988,626,000 USD
ADC Therapeutics SA (ADCT) 4,011,2155.23%98,435,216 USD
Silence Therapeutics plc (SLN) 4,397,2474.92%37,685,990 USD
Circassia Group Plc (CIR) 71,081,21717.0%34,396,201 USD
Innate Pharma (IPH) 7,485,5009.48%32,079,335 USD
PhaseBio Pharmaceuticals, Inc. (PHAS) 3,004,5546.28%9,103,799 USD
Pieris Pharmaceuticals, Inc. (PIRS) 3,584,2306.00%7,741,937 USD
Entasis Therapeutics Holdings Inc. (ETTX) 2,164,8555.80%4,535,371 USD
Markets and indexes
-
- Main Market
- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- Bloomberg Code :  AZN:LN
- Reuters Code :  AZN.L
- Datastream Code :  AZN
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire


Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : https://www.astrazeneca.com/investor-relations.html
Brand Portfolio
In partnership withAllbrands.markets
More brands of AstraZeneca PLC
Sector Other Pharmaceuticals
1st jan.Capitalization (M$)
ASTRAZENECA PLC7.37%145 472
JOHNSON & JOHNSON8.16%448 257
ROCHE HOLDING AG-1.80%290 657
PFIZER, INC.8.72%224 020
ABBVIE INC.8.66%205 641
NOVARTIS AG-3.78%200 099
MERCK & CO., INC.-4.29%198 235
NOVO NORDISK A/S12.23%179 620
ELI LILLY AND COMPANY16.21%178 360
BRISTOL-MYERS SQUIBB COMPANY4.59%144 867
AMGEN INC.9.33%144 431
SANOFI10.19%131 645
GLAXOSMITHKLINE PLC2.12%96 628
JIANGSU HENGRUI MEDICINE CO., LTD.-24.79%69 138
BAYER AG18.49%68 039
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-25.13%61 912
TAKEDA PHARMACEUTICAL COMPANY LIMITED-0.40%53 487
DAIICHI SANKYO COMPANY, LIMITED-23.55%47 335
CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRY (GROUP) INC.15.15%32 499
ASTELLAS PHARMA INC.5.02%28 423